NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI), SolarEdge Technologies, Inc. (NASDAQ:SEDG), and Barclays PLC (NYSE:BCS). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Class Period: August 15, 2022 - September 27, 2023
Lead Plaintiff Deadline: January 2, 2024
According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Brainstorm Cell downplayed the severity of the Food and Drug Administrations (FDA) refusal to file letter; (2) Brainstorm Cell continued to conceal the risks associated with the submission of the biologics license application (BLA); and (3) as a result, Defendants statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
For more information on the Brainstorm Cell class action go to: https://bespc.com/cases/BCLI
SolarEdge Technologies, Inc. (NASDAQ:SEDG)
Class Period: February 22, 2022 - October 19, 2023
Lead Plaintiff Deadline: January 2, 2024
The SolarEdge class action lawsuit ...